Abcuro drug fails muscle weakness trial, development to continue

Ali Nemati6 days ago25 sec read19 views

Abcuro's experimental drug missed its primary and key secondary endpoints in a Phase 2b/3 trial for treating a rare autoimmune condition without FDA-approved therapies. Despite the setback, Abcuro plans to continue development, highlighting the persistence needed in pharmaceutical research despite clinical failures. Content creators should emphasize the importance of resilience and continuous innovation in medical science communications.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

GSK to buy pulmonary hypertension biotech 35Pharma for $950M

GlaxoSmithKline (GSK) acquired 35Pharma for $950 million to gain access to their pulmonary hypertension drug program, expanding GSK's therapeutic port...GlaxoSmithKline (GSK) acquired 35Pharma for $950 million to gain access to their pulmonary hypertension drug program, expanding GSK's therapeutic portfolio. This move is significant as it enhances GSK’s presence in specialized pharmaceutical markets ...

Ali Nemati

Biotech & Pharma6 days ago31 sec read

Immedica wins accelerated approval for once-rejected rare disease drug

Swedish biotech Immedica received FDA accelerated approval for a drug addressing elevated plasma arginine levels in patients with the rare disease ARG...Swedish biotech Immedica received FDA accelerated approval for a drug addressing elevated plasma arginine levels in patients with the rare disease ARG1-D, marking a significant breakthrough after initial rejection. This approval offers new hope and t...

Ali Nemati

Biotech & Pharma6 days ago28 sec read

AI biotech Turbine raises $25M Series B to sell 'Virtual Lab' to pharma

Budapest-based biotech company Turbine secured $25 million in Series B funding to advance its 'Virtual Lab' technology, which simulates cell behavior ...Budapest-based biotech company Turbine secured $25 million in Series B funding to advance its 'Virtual Lab' technology, which simulates cell behavior using AI models, aiming to revolutionize pharmaceutical research processes. This investment undersco...

Ali Nemati

Biotech & Pharma6 days ago31 sec read

Astellas pays $240M cash for Vir's prostate cancer drug

Astellas Pharma agreed to pay $240 million in cash to Vir Biotechnology for an experimental prostate cancer drug, marking a significant deal as Vir tr...Astellas Pharma agreed to pay $240 million in cash to Vir Biotechnology for an experimental prostate cancer drug, marking a significant deal as Vir transitions its focus towards oncology. This partnership underscores the growing interest in innovativ...

Ali Nemati

Health & Medicine1 hour ago28 sec read

STAT+: Pharmalittle: We're reading about Trump's MFN deals, 340B program controversies, and much more

The Trump administration's most-favored nation drug pricing deals with 16 pharmaceutical companies are set to expire after three years, impacting drug...The Trump administration's most-favored nation drug pricing deals with 16 pharmaceutical companies are set to expire after three years, impacting drug prices for cash-paying customers and Medicaid; this has introduced uncertainty in Europe regarding ...

Ali Nemati

Abcuro drug fails muscle weakness trial, development to continue

Related Articles

GSK to buy pulmonary hypertension biotech 35Pharma for $950M

Immedica wins accelerated approval for once-rejected rare disease drug

AI biotech Turbine raises $25M Series B to sell 'Virtual Lab' to pharma

Astellas pays $240M cash for Vir's prostate cancer drug

STAT+: Pharmalittle: We're reading about Trump's MFN deals, 340B program controversies, and much more